Intranet Fakultät für Chemie und Pharmazie

Prof. Dr. Oliver Scherf-Clavel
Clinical Pharmacy and Pharmacotherapy

Address

Ludwig-Maximilians-Universität München
Department Pharmazie
Butenandtstr. 5
81377 München
Phone +49 89 2180 77092
Room-Nr. B2.095
Email

Research Interests

  • model-informed precision dosing of oral antineoplastic drugs
  • microsampling in bioanalytical context
  • Organ-on-Chip models to evaluate PK/PD-targets

Short CV

  • since 2023 W2 Professor of Clinical Pharmacy and Pharmacotherapy, Department of Pharmacy, LMU Munich
  • 2022 - 2023 W2 Professor of Biopharmaceutical Chemistry, Aalen University
  • 2017 - 2022 W1 Professor of Clinical Pharmacy, Institute for Pharmacy and Food Chemistry, JMU Wuerzburg
  • 2016 Postdoctoral Researcher, “Institut für Biomedizinische und Pharmazeutische Forschung (IBMP)” with Prof. Fritz Sörgel
  • 2015 Research fellow, European Directorate for the Quality of Medicines (EDQM) in Strasbourg (France)
  • 2012 - 2016 Dr. rer. nat. , Institute for Pharmacy and Food Chemistry, JMU Wuerzburg

Key publications

  • Zimmermann S., Aghai‐Trommelschlaeger F., Kraus S., Grigoleit G.U., Gesierich A., Schilling B.,Kalogirou C., Goebeler M.E., Kurlbaum M., Klinker H., Isberner N., Scherf‐Clavel O. Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib. J Pharm Biomed Anal (2023) 228:115311. doi: 10.1016/j.jpba.2023.115311
  • Isberner N., Gesierich A., Balakirouchenane D., Schilling B., Aghai‐Trommeschlaeger F., Zimmermann S., Kurlbaum M., Puszkiel A., Blanchet B., Klinker H., Scherf‐Clavel O. Monitoring of Dabrafenib and Trametinib in Serum and Self‐Sampled Capillary Blood in Patients with BRAFV600‐Mutant Melanoma. Cancers (2022) 14(19):4566. doi: 10.3390/cancers14194566
  • Isberner, N., Kraus, S., Grigoleit, G.U., Aghai, F., Kurlbaum, M., Zimmermann, S., Klinker, H., Scherf‐Clavel, O. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice – a prospective single‐center trial Cancer Chemotherapy and Pharmacology (2021), 88(6): 973‐983. doi: 10.1007/s00280‐021‐04351‐w
  • Gerner, B., Scherf‐Clavel, O. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment Pharmaceutics (2021), 13:778. doi: 10.3390/pharmaceutics13060778
  • Gerner, B.; Aghai-Trommeschlaeger, F.; Kraus, S.; Grigoleit, G.U.; Zimmermann, S.; Kurlbaum, M.; Klinker, H.; Isberner, N.; Scherf-Clavel, O. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics (2022), 14:2556. doi: 10.3390/pharmaceutics14122556